Xillix Technologies Corp

XLX-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about XLX-T

Signal
Opinion
Expert
BUY
BUY
June 21, 2004
Have a good technology and a well-run company. The question is, when do they get approval in the US for their commercialization of their ultraviolet scope.
Show full opinionHide full opinion
Have a good technology and a well-run company. The question is, when do they get approval in the US for their commercialization of their ultraviolet scope.
DON'T BUY
DON'T BUY
June 2, 2004
In the bottom 20% of their database. Moving ahead with FDA testing. Still expected to lose six cents in 2004. Should see improvement in four months.
Show full opinionHide full opinion
In the bottom 20% of their database. Moving ahead with FDA testing. Still expected to lose six cents in 2004. Should see improvement in four months.
DON'T BUY
DON'T BUY
May 31, 2004
Essentially has no revenues. Highly speculative. Has always found it difficult to profitably navigate through the diagnostic arena.
Show full opinionHide full opinion
Essentially has no revenues. Highly speculative. Has always found it difficult to profitably navigate through the diagnostic arena.
BUY
BUY
April 8, 2004
A pretty solid company. Have completely turned around after a dispute with a partner a several months ago. Should be able to move up 20/25% a year.
Show full opinionHide full opinion
A pretty solid company. Have completely turned around after a dispute with a partner a several months ago. Should be able to move up 20/25% a year.
DON'T BUY
DON'T BUY
March 29, 2004
Only likes companies that have good solid earnings. Too speculative.
Show full opinionHide full opinion
Only likes companies that have good solid earnings. Too speculative.
DON'T BUY
DON'T BUY
March 16, 2004
Could be an interesting speculation in a year/18 months. Watching it.
Show full opinionHide full opinion
Could be an interesting speculation in a year/18 months. Watching it.
BUY
BUY
February 27, 2004
Have an application before the FDA and approval is expected in May. Very speculative stock. Has pretty good opportunity because the technology is being used in Europe.
Show full opinionHide full opinion
Have an application before the FDA and approval is expected in May. Very speculative stock. Has pretty good opportunity because the technology is being used in Europe.
BUY WEAKNESS
BUY WEAKNESS
February 20, 2004
Likes the company, but it has had a huge run. May be it would get it $ .10/15 cheaper.
Show full opinionHide full opinion
Likes the company, but it has had a huge run. May be it would get it $ .10/15 cheaper.
BUY
BUY
February 12, 2004
An exciting stock. Have done a recent financing. Waiting for FDA approval. Getting geared up for sales in the states. Speculative.
Show full opinionHide full opinion
An exciting stock. Have done a recent financing. Waiting for FDA approval. Getting geared up for sales in the states. Speculative.
BUY
BUY
January 23, 2004
Solved their financial problems. Good technology. Well-managed. Starting to get traction. Could be a takeout candidate.
Show full opinionHide full opinion
Solved their financial problems. Good technology. Well-managed. Starting to get traction. Could be a takeout candidate.
BUY
BUY
January 20, 2004
Intrigued with the story. Going to do more work on it. Very speculative.
Show full opinionHide full opinion
Intrigued with the story. Going to do more work on it. Very speculative.
BUY
BUY
January 15, 2004
Strong CEO. Product has been approved in Europe. Have applied for FDA approval which is expected this spring. Once they get approval, expect they will hit the ground running. Speculative.
Show full opinionHide full opinion
Strong CEO. Product has been approved in Europe. Have applied for FDA approval which is expected this spring. Once they get approval, expect they will hit the ground running. Speculative.
BUY
BUY
November 7, 2003
New endoscopy for lung cancer diagnostics approved in Europe and should have FDA approval next year. Earnings have grown from a loss of 0.08¢ to a loss of 0.03¢. Very exciting opportunities.
Show full opinionHide full opinion
New endoscopy for lung cancer diagnostics approved in Europe and should have FDA approval next year. Earnings have grown from a loss of 0.08¢ to a loss of 0.03¢. Very exciting opportunities.
Showing 16 to 28 of 28 entries